[1] |
Toumi A, Yarrarapu SNS, Litaiem N. Wells syndrome[M/OL]. StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. https://www.ncbi.nlm.nih.gov/books/NBK532294/.
|
[2] |
Alvarez Martinez D, Laffitte E. A non⁃infectious cellulitis to know: Wells' syndrome[J]. Rev Med Suisse, 2021,17(732):610⁃614.
|
[3] |
Räßler F, Lukács J, Elsner P. Treatment of eosinophilic cellulitis (Wells syndrome) ⁃ a systematic review[J]. J Eur Acad Dermatol Venereol, 2016,30(9):1465⁃1479. doi: 10.1111/jdv.13706.
|
[4] |
Coattrenec Y, Ibrahim Yasmine L, Harr T, et al. Long⁃term remission of Wells syndrome with omalizumab[J]. J Investig Allergol Clin Immunol, 2020,30(1):58⁃59. doi: 10.18176/jiaci.0436.
|
[5] |
Yeon J, Chan RC, Zagarella S. Eosinophilic cellulitis successfully treated with methotrexate[J]. Australas J Dermatol, 2020,61(4):e421⁃e423. doi: 10.1111/ajd.13358.
|
[6] |
Blomberg M, Winther C, Høyrup S, et al. Treatment of widespread eosinophilic cellulitis (Wells' syndrome) with benralizumab[J]. Acta Derm Venereol, 2020,100(18):adv00332. doi: 10.2340/00015555⁃3697.
|
[7] |
Lu J, Wu W, Zhang M, et al. Wells syndrome successfully treated with tripterygium glycosides[J]. Clin Cosmet Investig Dermatol, 2021,14:1029⁃1031. doi: 10.2147/CCID.S328578.
|
[8] |
Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL⁃4 and IL⁃13 via IL⁃4Rα inhibition with dupilumab[J]. Expert Rev Clin Immunol, 2020,16(12):1115⁃1125. doi: 10.1080/1744666X.2021.1847083.
|